MindWalk HoldingsHYFT +5.40%38 Gross Margin % is 59.26% as of Jan. 2026, which is 7% above its 10-year median of 55.25. GuruFocus rates HYFT with a GF Score™ of 38/100 and a GF Value™ of $0.61 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 735 Biotechnology companies, MindWalk Holdings ranks worse than 53.74% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
MindWalk Holdings had a gross margin of 59.26% for the quarter that ended in Jan. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
MindWalk Holdings Gross Margin % Related Terms
MindWalk Holdings Gross Margin % Historical Data
* Premium members only.
The historical data trend for MindWalk Holdings's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HYFT vs ANVS, GANX, EXOZ: Gross Margin % Comparison
For the Biotechnology subindustry, MindWalk Holdings's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MindWalk Holdings Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MindWalk Holdings's Gross Margin % distribution charts can be found below:
* The bar in red indicates where MindWalk Holdings's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
MindWalk Holdings (HYFT) has a Gross Margin % of 59.26% as of Jan. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on MindWalk Holdings and its competitors. This is near median its historical median of 55.25. Over the past decade, MindWalk Holdings' Gross Margin % has ranged from 45.05 to 64.42. According to the industry distribution chart, MindWalk Holdings ranks #395 out of 735 companies in the Biotechnology industry, placing it in the top 53.7%.
Is MindWalk Holdings' Gross Margin % too high?
MindWalk Holdings' current Gross Margin % of 59.26% is near median its 10-year median of 55.25. Over the past 10 years, this metric has ranged from a low of 45.05 to a high of 64.42. The Biotechnology industry median Gross Margin % is 60.90. MindWalk Holdings' value of 59.26% is 2.7% below this industry median. Based on the distribution chart, MindWalk Holdings ranks #395 out of 735 companies in the Biotechnology industry, which is below the industry midpoint. Overall, MindWalk Holdings has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does MindWalk Holdings' Gross Margin % compare to ANVS and GANX?
According to the Biotechnology industry distribution chart, MindWalk Holdings ranks #395 out of 735 companies for Gross Margin %. This places MindWalk Holdings in the lower half of its industry. The industry median Gross Margin % is 60.90. MindWalk Holdings' value of 59.26% is 2.7% below this benchmark. Historically, MindWalk Holdings' own Gross Margin % has ranged from 45.05 to 64.42 over the past decade. While the company's 10-year median is 55.25 vs. the industry median of 60.90, MindWalk Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.90, based on 735 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MindWalk Holdings's current Gross Margin % of 59.26% is 2.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on MindWalk Holdings and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MindWalk Holdings's current Gross Margin % is 59.26%, which is near median its own 10-year median of 55.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MindWalk Holdings stock overvalued right now?
Based on GuruFocus' analysis, MindWalk Holdings (HYFT) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.61, compared to a current price of $1.66 — trading 172.1% above its estimated fair value. The current Gross Margin % is 59.26%, which is near median its 10-year median of 55.25 and 2.7% below the Biotechnology industry median of 60.90. MindWalk Holdings' overall GF Score™ is 38/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For MindWalk Holdings (HYFT), the current Gross Margin % is 59.26% as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MindWalk Holdings (HYFT) Overvalued in 2026?
Based on GuruFocus' analysis, MindWalk Holdings stock appears to be overvalued.
The current stock price of $1.66 is trading 172.1% above its estimated GF Value™ of $0.61.
GuruFocus considers MindWalk Holdings to be Significantly Overvalued.
Key valuation signals for HYFT:
Gross Margin %: 59.26% (near median its 10-year median of 55.25)
GF Value™: $0.61 vs. price of $1.66 (172.1% above fair value)
Industry Position: 2.7% below the Biotechnology median (#395 of 735)
No single metric tells the full story. See the HYFT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MindWalk Holdings Corp is a Bio-Native AI company transforming drug discovery and development. Powered by patented HYFT technology and the LensAI platform, MindWalk unifies sequence, structure, function, and literature into a single computational language and closes the loop with an integrated, full-stack wet lab. The platform supports rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics that help turn insights into validated candidates at speed.
38GF Score
Get the complete analysis for HYFT
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HYFT has been successfully added to your 
